Aporte del PET/CT con 18 FDG en el manejo de pacientes con cáncer desdiferenciado de tiroides atendidos en el Instituto Oncológico Dr. Juan Tanca Marengo, SOLCA – Guayaquil. 2011-2017.

Abstract

Background: Thyroid cancer is the most common malignant tumor originating in endocrine organs, occurring in more than 92%, among the tools for its prognostic assessment is positron emission tomography, a non-invasive Nuclear Medicine diagnostic technique capable of study the evolution of patients with thyroid cancer by capturing images that represent metabolic activity of the affected tissue. A correct evaluation of this technique will show us its real relevance in the evaluation of the evolution of the dedifferentiated thyroid cancer. Objective: To determine the utility of the PET 18 FDG technique in the screening of recurrences in dedifferentiated thyroid cancer . Methods: This is an observational, analytical transversal study, in which the necessary data were collected by reviewing the clinical histories of the patients who have attended the Dr. Juan Tanca Marengo Oncological Institute (SOLCA), over a period of six years that goes from 2011 to 2017. Results: Of a population of 117 patients with a previous diagnosis with thyroid cancer, 26 (22%) were male and 91 (78%) female, the frequency of predominantly histological type was classic Papillary type in 108 (92%) of the cases and only in 9 (8%) cases was follicular. Regarding the age, 29% of the patients are in an age range of 51-60 years (22%), 41-50 years 20%, 31-40 years (20%) 21-30 years (7%). Frequency of metastasis to locoregional target organs 60%, lung 32% and bone 15%. Significance between PET / CT versus other techniques such as CT and ECO (Sensitivity: 64.81%, Specificity: 88.89%, PPV: 98.59%, NPV: 17.39%) (OR: 14.73 ; p = 0.001 Conclusions: Finally, with respect to the PET / CT technique with FDG, it is shown that it has greater sensitivity and specificity compared to other imaging methods such as ultrasound and CT, being more sensitive for loco regional metastasis and indicated for patients with body scan with negative results.